Physician profile
Antonio Serna
NPI 1538208541
$8,790.77
in general payments reported to CMS, 2019-2025
34 companies · $820 in 2025
The $820 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,978 · 2020: $696 · 2021: $2,926 · 2022: $1,069 · 2023: $731 · 2024: $571 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,105 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.49 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,253.80 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Redhill Biopharma INC. | $1,998.33 | 2020-2024 | Talicia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $690.26 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $516.42 | 2019-2025 | Tremfya, Stelara |
| Gi Supply, INC. | $511.70 | 2019 | |
| Olympus America INC. | $403.93 | 2020-2021 | |
| Gilead Sciences, INC. | $392.40 | 2019-2025 | |
| Allergan, INC. | $312.65 | 2019-2020 | |
| Shionogi INC | $251.02 | 2019 | |
| Pfizer INC. | $173.54 | 2019-2023 | |
| Axonics, INC. | $152.59 | 2023 | Axonics |
| Ironwood Pharmaceuticals, INC | $128.08 | 2019-2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $122.85 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $114.21 | 2019-2020 | |
| Celgene Corporation | $110.16 | 2021-2023 | Zeposia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $107.89 | 2025 | Fibroscan |
| Lilly USA, LLC | $63.28 | 2024-2025 | Omvoh |
| Micro-Tech Endoscopy USA, INC. | $62.72 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $52.97 | 2023 | Dificid |
| Qol Medical, LLC | $46.84 | 2022 | |
| Evoke Pharma, INC. | $44.02 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.45 | 2021-2025 | Eohilia |
| Alfasigma USA, INC. | $36.21 | 2020 | |
| Ucb, INC. | $35.26 | 2019 | |
| Ferring Pharmaceuticals INC. | $29.81 | 2019 | |
| Romark Laboratories, Lc | $25.63 | 2020 | |
| Braintree Laboratories, INC. | $24.41 | 2019-2021 | |
| Shire North American Group INC | $18.48 | 2019 | |
| Novo Nordisk INC | $18.27 | 2025 | Wegovy |
| Medtronic, INC. | $15.32 | 2024 | Gi Genius |
| Cumberland Pharmaceuticals, INC. | $13.40 | 2020 | |
| Genzyme Corporation | $12.75 | 2023 | |
| Endogastric Solutions, INC | $8.12 | 2023 | Esophyx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$33,417.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Serna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.